|
J Biol Chem, Vol. 275, Issue 13, 9332-9339, March 31, 2000
Intracellular Activation of Rat Hepatic Lipase Requires Transport
to the Golgi Compartment and Is Associated with a Decrease in
Sedimentation Velocity*
Adrie J. M.
Verhoeven ,
Bernadette P.
Neve, and
Hans
Jansen
From the Department of Biochemistry, Cardiovascular Research
Institute (COEUR), Erasmus University Rotterdam, 3000 DR
Rotterdam, The Netherlands
 |
ABSTRACT |
Hepatic lipase (HL) is an
N-glycoprotein that acquires triglyceridase activity
somewhere during maturation and secretion. To determine where and how
HL becomes activated, the effect of drugs that interfere with
maturation and intracellular transport of HL protein was studied using
freshly isolated rat hepatocytes. Carbonyl cyanide
m-chlorophenyl hydrazone (CCCP), castanospermine, monensin,
and colchicin all inhibited secretion of HL without affecting its
specific enzyme activity. The specific enzyme activity of intracellular
HL was decreased by 25-50% upon incubation with CCCP or
castanospermine, and increased 2-fold with monensin and colchicin.
Glucose trimming of HL protein was not affected by CCCP, as indicated
by digestion of immunoprecipitates with jack bean -mannosidase.
Pulse labeling experiments with [35S]methionine indicated
that conversion of the 53-kDa precursor to the 58-kDa form, nor the
development of endoglycosidase H-resistance, were essential for
acquisition of enzyme activity. In sucrose gradients, HL protein from
secretion media sedimented as a homogeneous band of about 5.8 S,
whereas HL protein from the cell lysates migrated as a broad band
extending from 5.8 S to more than 8 S. With both sources, HL activity
was exclusively associated with the 5.8 S HL protein form. We conclude
that glucose trimming of HL protein in the endoplasmic reticulum is not
sufficient for activation; full activation occurs during or after
transport from the endoplasmic reticulum to the Golgi and is associated
with a decrease in sedimentation velocity.
 |
INTRODUCTION |
Hepatic lipase (HL)1 is
an extracellular enzyme present in the liver of most vertebrates. The
enzyme is synthesized and secreted by liver parenchymal cells, and
subsequently bound in the space of Disse, where it plays an important
role in plasma lipoprotein metabolism (1-3). HL hydrolyzes
phospholipids and triacylglycerols present in high and intermediate
density lipoproteins, and facilitates the hepatic uptake of remnant
particles (4-6) and of cholesterol(esters) carried in high density
lipoproteins (7, 8). In addition, HL may act as a ligand protein for
remnant binding to the liver (9). In humans, a low HL activity is
associated with an increased atherosclerotic risk (10, 11). When
expressed in transgenic mice, human HL was shown to markedly reduce the
accumulation of aortic cholesterol (12). HL may protect against
development of premature atherosclerosis by contributing to reverse
cholesterol transport and reducing the number of atherogenic remnants
in the circulation. Expression of HL in the liver is under hormonal and dietary control, which may be exerted at the level of synthesis, intracellular processing, secretion, extracellular binding, and internalization.
When studying the post-translational control of HL expression in
suspensions of freshly isolated rat hepatocytes, we noted that newly
synthesized HL acquires catalytic activity toward triacylglycerols somewhere along the secretory pathway (13). First, the specific enzyme
activity of intracellular HL was 3-5-fold lower than that of secreted
HL. Second, HL activity secreted by hepatocytes in the absence of
protein de novo synthesis was 5-fold higher than was
accounted for by the fall in the intracellular HL activity. Such an
apparent activation was also observed for human HL in the HepG2
hepatoma cell line (14). HL is a glycoprotein bearing two (rat) to four
(human) asparagine-linked glycans (15-17). For the synthesis and
secretion of fully active HL, N-glycosylation is a
prerequisite (18, 19). When glycosylation is prevented, either by
tunicamycin or by site-directed mutagenesis, inactive HL protein
accumulates intracellularly (16, 20). Along the secretory pathway, the
N-linked oligosaccharide chains are extensively processed.
In rat hepatocytes treated with castanospermine, a selective RER
glucosidase inhibitor which prevents secretion of newly synthesized HL,
inactive HL was present; upon removal of the inhibitor, the HL protein
acquired catalytic activity and was secreted (13). These observations
show that newly synthesized HL protein becomes catalytically active
during oligosaccharide processing after the terminal glucose residues
have been removed by the glucosidases in the RER, and suggest that
activation may be intimately linked to the glycosylation state of the
HL protein.
The presence of terminal glucoses on HL protein itself may prevent the
acquisition of catalytic activity. However, the glucose residues on
N-glycoproteins have recently been implicated in the protein
folding and quality control system of the RER, which prevents malfolded
proteins from reaching the Golgi (21, 22). It is possible therefore,
that glucose trimming is only required for transport of the newly
synthesized HL out of the RER and that activation occurs subsequently
in a distal compartment of the secretory pathway. In line with this,
inhibition of the Golgi mannosidase I with 1-deoxymannojirimycin has no
effect on either activation or secretion of HL in rat hepatocytes (13,
19). This suggests that once the glucose residues have been removed, activation and subsequent secretion proceed independently of further oligosaccharide processing.
If glucose trimming in the RER is necessary for activation of HL
protein itself rather than for transport of newly synthesized HL
protein out of the RER, one would expect that inhibition of the
transport process leads to the intracellular accumulation of active HL
protein. The present study was performed to test this possibility. We
determined in which intracellular compartment HL protein is activated,
by using inhibitors that primarily affect vesicular transport in the
secretory pathway. CCCP, monensin, and colchicin inhibit transport of
glycoproteins from the RER to the Golgi (23, 24), from medial- to
trans-Golgi (25) and between the Golgi and the plasma membrane (26,
27), respectively. Our data show that active HL accumulates in
monensin- and colchicin-treated hepatocytes, but not in cells treated
with CCCP. Hence, glucose trimming alone does not activate HL but is
necessary for translocation of HL protein to the Golgi compartment,
where the protein apparently acquires its triglyceridase activity.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Carbonyl cyanide m-chlorophenyl
hydrazone (CCCP), monensin, and ketoconazole were purchased from
Calbiochem (La Jolla, CA), whereas colchicin was from Merck (Darmstadt,
Germany). Castanospermine, 1-deoxymannojirimycin, jack bean
-D-mannoside mannohydrolase ( -mannosidase), and CHAPS
were from Roche Molecular Biochemicals (Germany).
Endo- -N-acetylglucosaminidase H was from Genzyme (Boston, MA). Protease inhibitors were from Sigma, except for Trasylol which was
from Bayer (Mijdrecht, Holland). Tran35S-label (1100 Ci/mmol) was obtained from ICN (Costa Mesa, CA), and glycerol
[1-14C]trioleate (50-80 mCi/mmol) was from Amersham
Pharmacia Biotech. Ham's F-10 and methionine-free minimal essential
medium were purchased from Life Technologies, Inc. (Breda, Holland),
whereas bovine serum was from BioTrading (Wilnis, Holland). Heparin was
from Leo Pharmaceuticals (Weesp, Holland). Goat and rabbit anti-HL antisera were raised against rat HL purified from liver heparin perfusates according to Jensen and Bensadoun (28); from the antisera
partly purified IgG fractions were prepared by precipitation in 50%
saturated ammonium sulfate followed by 17% (w/v)
Na2SO4, as described previously (13). Alkaline
phosphatase-conjugated goat anti-rabbit IgG was obtained from Tago
(Burlingame, CA), and p-nitrophenol phosphate was from
Merck. Broad-range protein size markers were from Bio-Rad. All other
chemicals were from Sigma. Polystyrene 96-well EIA plates (code 3590)
were from Costar (Cambridge, MA).
Hepatocyte Isolation and Incubation--
Hepatocytes were
isolated from male Wistar rats (200-250 g body weight) by collagenase
perfusion: non-parenchymal cells were removed by differential
centrifugation (29). Cell viability was determined by trypan blue
exclusion and ranged from 85 to 90%. The cells were suspended at a
density of 4 × 106 cells/ml in minimal essential
medium containing 25 units/ml heparin and 20% of dialyzed,
heat-inactivated bovine serum (30). Cell suspensions were incubated at
37 °C under an atmosphere of 5% CO2, 95%
O2 in a shaking water bath. The incubations were started with the addition of inhibitors. CCCP, monensin, and colchicin were
added from 1000-fold stock solutions in ethanol; other inhibitors were
added from 100-fold stocks in PBS. At the times indicated, samples of
the cell suspension were collected on ice. The cells were separated
from the medium by centrifugation for 5 s at 10,000 × g. The cells were washed once in PBS and then resuspended at 15 × 106 cells/ml in a 40 mM
NH4OH buffer, pH 8.1 (31), containing 25 units/ml heparin
and a mixture of protease inhibitors (1 mM EDTA, 10 units/ml Trasylol, 0.1 mM benzamidine, and 2 µg/ml each
of leupeptin, antipain, chymostatin, and pepstatin). After 30 min on
ice, the lysates were sonicated for 15 s (MSE Soniprep 150, amplitude 14 µm) and centrifuged for 10 min at 10,000 × g and 4 °C. The supernatants were used for analysis of
intracellular HL. Cell-free media and cleared lysates were rapidly
frozen in liquid nitrogen and stored at 80 °C until use.
Hepatic Lipase Activity--
Hepatic lipase activity was
determined by a triacylglycerol hydrolase assay at pH 8.5 in 0.6 M NaCl using a gum acacia-stabilized glycerol
[14C]trioleate emulsion as substrate (19). Assays were
performed for 30 min at 30 °C. Activities were expressed as
milliunits (nanomoles of free fatty acids released per min). In a total
assay volume of 125 µl, release of free fatty acids was linear with
time and sample volume up to 50 µl for the cell-free media and 10 µl for the cell lysates.
In immuno-inhibition assays, 40 µl of the cell-free media or 10 µl
of the cell lysates were preincubated for 1 h on ice in a total
volume of 50 µl with either 100 µg of goat non-immune IgGs or
anti-rat HL IgGs. Thereafter, 75 µl of substrate was added to the
supernatant, and the residual immunoresistant triglyceridase activity
was determined. The lipase activity in the extracellular media was
completely inhibited by the anti-HL IgGs whereas 85-95% of the lipase
activity in the cell lysates was sensitive to immuno-inhibition.
Hepatic Lipase Mass--
The amount of HL protein was determined
by a solid-phase enzyme-linked immunosorbent assay in which the antigen
was sandwiched between goat and rabbit polyclonal anti-HL IgGs. EIA
plate wells were coated with 20 µg of goat anti-HL IgGs. After
blocking with 1% bovine serum albumin in PBS, the wells were incubated
successively with: (i) sample, either 50 µl of cell-free medium or 5 µl of cell lysate; (ii) 3 µg/ml rabbit anti-HL IgGs in PBS, and
(iii) alkaline phosphatase-conjugated goat anti-rabbit IgG at a 1:1500 dilution in PBS. Finally, the presence of alkaline phosphatase was
detected with p-nitrophenol phosphate as substrate. Color development was stopped with NaOH (1 M, final
concentration), and the absorbance at 405 nm was measured in a
Molecular Devices microplate reader. Absorbances were read against a
standard curve prepared for each plate by serial dilutions of rat HL
partly purified from liver heparin perfusates by affinity
chromatography on Sepharose-heparin; HL activity was eluted from the
column by a linear salt gradient and the peak fractions were pooled.
After adding bovine serum albumin to a final concentration of 1%,
aliquots were frozen in liquid nitrogen and stored at 80 °C until use.
Pulse Labeling with [35S]Methionine--
Freshly
isolated rat hepatocytes were incubated in methionine-free minimal
essential medium in the absence or presence of inhibitors, as described
above. After 1 h, 80 µCi of Tran35S-label was added
per ml of cell suspension, and the incubation was continued for the
time indicated. The incubations were stopped on ice, and the cells and
media were separated by centrifugation (5 s, 10,000 × g). The cell-free medium was collected in vials containing
cold methionine (final concentration 1 mM) and the mixture
of protease inhibitors described above. After washing twice with cold
PBS, the cells were lysed in cold PBS containing 1% Triton X-100, 1%
sodium deoxycholate, 0.25% SDS, 1 mM methionine, 25 units/ml heparin, 10 mM HEPES, pH 7.4, and the mixture of
protease inhibitors. After 30 min on ice, the lysates were centrifuged for 10 min at 10,000 × g and 4 °C, and the
supernatants were used for further analysis.
Immunoprecipitations and Glycosidase Digestions--
HL protein
was immunoprecipitated from cell-free media and cell lysates by
overnight incubation at 4 °C with 50 µl of a 50% slurry of goat
anti-HL IgGs immobilized onto Sepharose (13). The beads were collected
by centrifugation (20 s, 10,000 × g), and washed twice
in successively: (i) 1% Triton X-100 in PBS, (ii) 1 M NaCl
in PBS, and (iii) PBS (all containing 1 mM
phenylmethylsulfonyl fluoride). For digestion with jack bean
-mannosidase (JBAM), the beads were resuspended in 100 µl of a 50 mM sodium acetate buffer, pH 5.0, containing 5 mM Zn2+, and then incubated overnight with or
without 50 µg of JBAM. Thereafter, the immunoprecipitated proteins
were released by boiling for 5 min in Laemmli's sample buffer without
2-mercaptoethanol, and the beads were removed by centrifugation. After
treating with 2-mercaptoethanol, the released proteins were separated
by SDS-PAGE using 7.5% gels. For digestion with Endo-H, the
immunoprecipitates were resuspended in 50 mM
NaPi, pH 6.0, containing 0.5% SDS, and the proteins were
released from the beads by boiling for 5 min. The eluate was diluted in
50 mM NaPi, pH 6.0, to reduce the concentration of SDS to 0.2%, and then incubated overnight at 37 °C in the
presence or absence of 40 milliunits/ml of Endo-H. After addition of
Laemmli's sample buffer and boiling for 5 min, the proteins were
separated by SDS-PAGE using 7.5% gels.
After SDS-PAGE, the gels were Coomassie-stained for estimation of
molecular sizes. The 35S-labeled proteins were visualized,
and their radioactivity quantified, by exposure of the dried gels to a
phosphor screen (Bio-Rad GS-363 Molecular Imager System, Hercules, CA).
Sensitivity to JBAM or Endo-H was indicated by an increase in
electrophoretic mobility.
Overall Protein de Novo Synthesis--
Incorporation of
[35S]methionine into trichloroacetic acid-precipitable
material was taken as a measure for overall protein de novo
synthesis. Incubations were performed as described above. Of the
cell-free media and lysates, 5-µl aliquots were spotted in duplicate
onto Whatman 3MM filters, and trichloroacetic acid precipitation was
performed as described previously (19). The radioactivity on the
filters was measured using the Molecular Imager System. The duplicate
measurements, which never differed by more than 5%, were averaged. The
data were corrected for the trichloroacetic acid-precipitable material
in the media and lysates of a control cell suspension that was put on
ice before addition of Tran35S-label.
Sucrose Velocity Gradient Centrifugation--
Hepatocytes were
incubated for 3 h with heparin, and cell-free medium was prepared
as described above. Cells were lysed in PBS containing 8 mM
CHAPS, 25 units/ml heparin and the mixture of protease inhibitors.
After 30 min on ice, the lysates were cleared by centrifugation (10 min, 10,000 × g, 4 °C). Of the secretion media and
cleared lysates, 200-µl aliquots were layered on top of linear
5-20% (w/w) sucrose gradients (4.0 ml) in 2 mM MOPS buffer, pH 8.0, 4 mM CHAPS, and 25 units/ml heparin. The
gradients were run at 40,000 rpm for 15 h at 4 °C in a Beckman
SW60 rotor (Beckman Instruments). Gradients were collected in 0.32-ml
fractions by aspiration from the bottom of the tubes. Total recovery of HL activity from the sucrose gradients was 95 ± 10 and 135 ± 25% (means ± S.D., n = 5) for secretion media
and cell lysates, respectively. The sedimentation markers bovine
albumin (s20,w = 4.3 S) and rabbit IgG
(s20,w = 7 S) were run in parallel; their position
in the sucrose gradients was determined by Coomassie staining (32).
Statistics--
All data are expressed as mean ± S.D.
Differences were tested statistically by one-way analysis of
variance followed by the Student-Newman-Keuls test, and considered
significant at p < 0.05 (33).
 |
RESULTS |
Effect of CCCP on HL Synthesis and Secretion--
When freshly
isolated rat hepatocytes were incubated for 3 h in the presence of
heparin, HL activity in the cell lysates remained almost constant at
4.3 ± 1.3 milliunits/ml (n = 6), which equals 0.27 ± 0.08 milliunits/106 cells. During this
incubation, HL activity in the extracellular medium increased from
0.4 ± 0.1 to 9.1 ± 2.6 milliunits/ml, which corresponds to
2.3 ± 0.6 milliunits/106 cells. In the presence of
increasing concentrations of CCCP, the extracellular appearance of HL
activity gradually fell (Fig. 1A). Complete inhibition was
obtained with 20 µM CCCP and above. Intracellular HL
activity decreased to 63 ± 10% (n = 3) of
controls when cells were incubated with 10 µM CCCP; a
further increase in the CCCP concentration did not have an additional
effect on intracellular HL activity. To study the effect of CCCP on
de novo synthesis of HL protein,
[35S]methionine was included during the last hour of
incubation. Fig. 1B shows that CCCP induced a
dose-dependent reduction in the 35S
radioactivity of HL protein immunoprecipitated from the media plus
lysate (53 + 58 kDa bands; see below). This parallelled the effect of
the inhibitor on incorporation of 35S radioactivity into
trichloroacetic acid-precipitable material, and hence on overall
protein synthesis (not shown). With 20 µM CCCP and above,
HL and overall protein synthesis were completely blocked. When
incubated with CCCP up till 10 µM, [35S]HL
in immunoprecipitates from the cell lysates was hardly affected, whereas [35S]HL in the extracellular media was highly
sensitive to inhibition. With 10 µM CCCP, where HL
synthesis was reduced by approximately 30%, the newly synthesized HL
protein was no longer secreted into the extracellular medium but
remained in the cells.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of CCCP on synthesis and secretion of
HL. Freshly isolated rat hepatocytes were incubated for 3 h
in the presence of different concentrations of CCCP. At the end of the
incubation, the HL activity in the cell-free media ( ) and cell
lysates ( ) was measured (panel A). Data are expressed as
percentage of the activity found for the control incubation, which was
9.1 and 4.3 milliunits/ml in the cell-free medium and cell lysate,
respectively. In parallel incubations, 80 µCi/ml
Tran35S-label was added after 1 h of preincubation
with CCCP (panel B). The incubation was continued for an
additional hour and then cell-free media ( ) and cell lysates ( )
were prepared. HL protein was immunoprecipitated by overnight
incubation with goat anti-HL IgGs coupled to Sepharose. The
immunoprecipitated proteins were separated by SDS-PAGE and the
radioactivity in the immunoreactive bands at the 53-58-kDa position in
the gels were quantified by PhosphorImaging. The sum of the
radioactivity in the bands from the lysate and cell-free medium was
taken as a measure for total synthesis of HL protein ( ). Data are
expressed as percentage of the radioactivity present in the
corresponding bands from control media and lysate. The results are
representative for two similar experiments.
|
|
Pulse-chase experiments were performed to study the effect of CCCP on
maturation of newly synthesized HL protein. After a 5-min pulse with
[35S]methionine, 35S-labeled HL migrated as a
53-kDa protein (Fig. 2). During the subsequent chase of control cells, the 53-kDa protein was converted into a 58-kDa protein with a half-life of approximately 20 min. Pulse
labeling of cells that had been preincubated with 10 µM CCCP also resulted in a 35S-labeled HL protein with
apparent molecular mass of 53 kDa. During the chase in the presence of
CCCP, the 53-kDa HL protein matured into the 58-kDa form but at a
much lower rate. The 58-kDa form appeared only after 30 min chase;
approximately 50% of the 53-kDa form had matured into the 58-kDa form
after 45 min of chase. The 53-kDa band was sensitive to digestion with
Endo-H, whereas the 58-kDa band was Endo-H resistant (see below).
Hence, CCCP retarded the maturation of the 53 kDa, high-mannose type
precursor form into the 58-kDa complex-type form of HL. Taken together,
the effects of CCCP on HL maturation and secretion are in
agreement with its proposed action as inhibitor of the RER-to-Golgi
transport.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of CCCP on HL maturation.
Hepatocytes were preincubated for 45 min with or without 10 µM CCCP. The cells were pulsed for 5 min with
[35S]methionine, and after washing, the cells were chased
in control medium (Con) or in medium containing 10 µM CCCP, respectively. At the times indicated, samples
were withdrawn and put on ice. HL was immunoprecipitated from the whole
cell suspensions and analyzed by SDS-PAGE and PhosphorImaging. The
apparent molecular weight of the bands is indicated in kDa.
|
|
Comparison between Effects of CCCP and Castanospermine--
The
effect of 10 µM CCCP on HL expression was compared with
that of 100 µg/ml castanospermine, which inhibits RER-to-Golgi transport of N-glycoproteins by interfering with
oligosaccharide processing. After 3 h of incubation, both HL
activity and HL protein were reduced in the extracellular medium of
CCCP-treated cells by approximately 85% compared with controls,
whereas with castanospermine, both parameters were decreased in
parallel by 65% (Table I). The specific
enzyme activity of secreted HL was about 45 milliunits/µg, which was
not significantly affected by either treatment. Under the conditions
used, the specific enzyme activity of HL in the control cell lysates
was only 50% of that in the cell-free media. Upon treating the cells
with CCCP, the amount of intracellular HL protein was hardly affected,
although simultaneously, HL activity decreased by approximately 35%
(Table I). Hence, the specific enzyme activity of intracellular HL was
25% lower in CCCP-treated cells than in control cells. In the presence
of CSP, both HL protein and HL activity in the cells were significantly
reduced compared with controls, but the effect on HL activity was
stronger than on HL protein. As a result, the specific enzyme activity
of residual HL fell by approximately 50%. In parallel incubations, the
effect of the inhibitors on overall protein de novo
synthesis was determined. Incorporation of
[35S]methionine into total trichloroacetic
acid-precipitable material was reduced to 52.5 ± 24.4 and
71.2 ± 8.1% of control by CCCP and CSP, respectively
(n = 3).
View this table:
[in this window]
[in a new window]
|
Table I
Effect of castanospermine and CCCP on intracellular and extracellular
HL
Freshly isolated rat hepatocytes were incubated for 3 h in the
presence of heparin without further additions (control), or with 10 µM CCCP or 100 µg/ml castanospermine (CSP). Then,
cell-free media and cell lysates were assayed for HL activity and HL
protein. Data are expressed as mean ± S.D. for three-five
independent experiments.
|
|
To test whether CCCP also interferes with oligosaccharide processing in
the RER, the glucose trimming status of the glycan chains on newly
synthesized HL protein was evaluated with JBAM (34, 35). Digestion of
high mannose-type glycoproteins with this exomannosidase will remove
five mannose residues from oligosaccharides bearing terminal glucose
residues (Glc1-3Man9GlcNAc2), but eight mannoses from completely glucose-trimmed glycan chains
(Man9GlcNAc2). The mobility of the
35S-labeled 58-kDa HL protein band present in control cells
and secretion media, was not affected by incubation with JBAM (Fig. 3), which agrees with the conclusion that
this protein reflects mature HL bearing complex-type oligosaccharides.
Upon digestion with JBAM, the 53-kDa band present in the control cells
was converted into two higher mobility bands with apparent molecular
masses of 52 and 49 kDa, which may reflect HL protein with incompletely and fully glucose-trimmed glycans, respectively. A similar digestion pattern was observed for the 53-kDa 35S-labeled HL protein
present in CCCP-treated cells. In contrast, [35S]HL that
is retained in CSP-treated cells predominantly migrated as a 55-kDa
band whose mobility was increased to approximately 52 kDa upon
treatment with JBAM. These observations suggest that CCCP inhibits
transport of de novo synthesized HL protein out of the RER
without interfering with glucose trimming.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 3.
Evaluation of glucose trimming status of HL
protein by digestion with jack bean
-mannosidase. Hepatocytes were preincubated
for 45 min in the absence (Con) or presence of 10 µM CCCP or 100 µg/ml CSP, and then labeled for 30 min
with [35S]methionine. After immunoprecipitation from the
cell free media (M) and from the cell lysates
(Cell), HL protein was incubated overnight without ( ) or
with (+) JBAM. The proteins were then resolved by SDS-PAGE and analyzed
by PhosphorImaging. The apparent molecular weight of the radioactive
bands is indicated in kDa.
|
|
Effect of Monensin and Colchicin--
In the presence of 50 µM monensin, secretion of HL activity was instantaneously
and almost completely inhibited (Fig.
4A). After 2 h of
incubation, HL activity in the extracellular medium was 14 ± 4%
(n = 4) of parallel controls. Simultaneously, the intracellular HL activity increased linearly with time to 250 ± 44% (n = 4) of control cells (Fig. 4B).
Under these conditions, [35S]methionine incorporation
into total protein was 44.2 ± 13.1% of control
(n = 3). Half-maximal effects of monensin on
extracellular and intracellular HL activity were obtained with 5 ± 2 µM (n = 3), which is much higher
than the concentrations that inhibit transport across the Golgi in
other cell types. At this concentration, secretion of HL activity was
almost completely inhibited during the first 60 min of incubation, but
thereafter, secretion proceeded at a rate similar to that in untreated
control suspensions. With other concentrations of monensin, secretion
of HL activity also started after an initial inhibitory period; this
lag time increased with the amount of monensin used. Apparently, in our
suspensions of freshly isolated rat hepatocytes, monensin loses its
efficacy in a time- and dose-dependent manner. Rapid
detoxification of monensin has been shown to occur in freshly isolated
rat liver microsomes by the cytochrome P-450 3A system, where it can be inhibited by competing substrates such as ketoconazole (36). When we
co-incubated intact rat hepatocytes with 25 µM
ketoconazole, the dose-response curve for monensin was shifted to
markedly lower concentrations (data not shown); half-maximal effects on
HL secretion and intracellular HL activity were now obtained with
0.3 ± 0.1 µM monensin (n = 3). This
effective dose suggests that monensin affects HL secretion and
intracellular HL activity through its inhibitory effect on Golgi
function. Due to its rapid detoxification in freshly isolated rat
hepatocytes, much higher concentrations of monensin are needed to
maintain an effective dose throughout the 2-3-h incubation period.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of monensin and colchicin on
extracellular and intracellular HL activity. Freshly isolated rat
hepatocytes were incubated in the absence ( ) or presence of 50 µM monensin ( ) or 50 µM colchicin ( ).
At the indicated times, aliquots of the cell suspension were collected
from the incubation, and HL activity was measured in the cell-free
media (panel A) and cell lysates (panel B). Data
are representative for two similar experiments.
|
|
In the presence of 50 µM colchicin, the secretion rate of
HL activity was reduced to 45 ± 9% of controls (Fig.
4A), whereas intracellular HL activity gradually increased
to 236 ± 34% of controls (n = 4) after 2 h
of incubation (Fig. 4B). Protein de novo
synthesis was reduced to 71.7 ± 16.6% of control
(n = 3). Immuno-inhibition assays using anti-HL IgGs
confirmed that HL was responsible for the observed changes in
intracellular and secreted triglyceridase activity.
After 2 h of incubation with 50 µM monensin or
colchicin, the amount of HL protein in the extracellular medium was
reduced in parallel with HL activity, similar to the effects observed with castanospermine and CCCP (Fig.
5A). In the cell lysates, the
amount of HL protein increased to 136 ± 21 and 137 ± 22%
of control values (n = 4) with monensin and colchicin,
respectively (Fig. 5B). These increases in intracellular HL
protein were significantly less than the concomitant change in
intracellular HL activity (p < 0.05; n = 4). As a result, the specific enzyme activity of intracellular HL was
increased with both inhibitors.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of various inhibitors on intracellular
and extracellular HL activity and amount of HL protein.
Hepatocytes were incubated for 3 h in the absence (CON)
or presence of 100 µg/ml CSP, 10 µM CCCP, 50 µM monensin (MON), 50 µM
colchicin (COL), or 1 mM 1-deoxymannojirimycin
(DMM). At the end of the incubation, cell-free media
(panel A) and cell lysates (panel B) were
prepared and HL activity (open bars) and the amount of HL
protein (hatched bars) were measured. Data are mean ± S.D. for three to six experiments and are expressed as percentage of
control, which was 8.8 ± 3.0 and 4.3 ± 1.3 milliunits/ml
for secreted and intracellular HL activity, and 0.19 ± 0.05 and
0.18 ± 0.03 µg/ml for secreted and intracellular HL protein,
respectively. Statistically significant differences from the
corresponding controls are indicated by asterisks
(p < 0.05). In panel C, the specific enzyme
activity of HL in the extracellular medium (gray bars) and
cell lysate (closed bars) was calculated from the mean HL
activity and HL protein found for each condition in the medium and cell
lysate, respectively.
|
|
Specific Triglyceridase Activity of HL--
The effects of the
different agents on the specific enzyme activity of HL are summarized
in Fig. 5C. Under all conditions, the specific enzyme
activity of secreted HL remained constant at approximately 45 milliunits/µg of HL. In control cells, the specific enzyme activity
of intracellular HL was much lower than of secreted HL. The specific
activity was further reduced by 25 and 50% upon treating the cells
with CCCP and castanospermine, respectively. In monensin- and
colchicin-treated cells, the specific activity was increased to levels
close to that of secreted HL. In the presence of 1 mM
1-deoxymannojirimycin, an inhibitor of Golgi mannosidase I, neither
secretion of HL (Fig. 5A) nor intracellular HL (Fig.
5B) were altered. Hence, the specific enzyme activity of
intracellular and secreted HL was not affected (Fig. 5C)
despite changes in the glycosylation state of secreted HL (see below). Taken together, these observations suggest that the catalytic activity
of HL increases upon transport from the RER to the Golgi compartment.
Activation and Apparent Molecular Mass of HL--
Hepatocytes were
incubated for 3 h with the various inhibitors, and
[35S]methionine was present during the last 2 h.
[35S]HL immunoprecipitated from control media migrated as
a single band of approximately 58 kDa (Fig.
6A). The
35S-labeled HL secreted by CCCP- and colchicin-treated
cells also migrated at the position of 58 kDa, but the radioactivity
was reduced to 35 and 17% of control, respectively. In the presence of
monensin, secretion of [35S]HL was decreased to 3% of
control, and the radioactive band migrated at a slightly higher
mobility than the 58-kDa band in the other secretion media (Fig.
6A). [35S]HL immunoprecipitated from control
lysates appeared as two bands on SDS-PAGE, a band of approximately 53 kDa, and a band of 58 kDa that co-migrated with [35S]HL
from the cell-free media (Fig. 6B). The total
35S radioactivity in HL immunoprecipitated from
CCCP-treated cells was similar to control cells, whereas in monensin-
and colchicin-treated cells total 35S-labeled HL was
2-2.5-fold higher. In lysates prepared from CCCP-treated cells, the
radioactivity of the 53-kDa band was increased whereas that of the
58-kDa band was decreased (Fig. 6B). In colchicin-treated cells, the 35S label in the 53- and 58-kDa bands were
increased in parallel. In contrast, the accumulation of
[35S]HL radioactivity in the monensin-treated cells only
occurred in the 53-kDa band; in addition, the largest band migrated at a mobility that was slightly higher than the 58-kDa band found in the
other cells. Comparison of the data in Fig. 6 with the effect of the
inhibitors on intracellular and secreted HL activity indicated that HL
activity varied in parallel with the expression of the 58-kDa protein
form, except for the monensin-treated cells, where intracellular HL
activity increased in parallel with the 53-kDa protein form.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of various inhibitors on the
electrophoretic mobility of HL. Cells were incubated for 3 h
in the absence (CON) or presence of 10 µM CCCP
(CCCP), 50 µM monensin (MON), or 50 µM colchicin (COL). During the last 2 h
of the incubation, 80 µCi/ml Tran35S-label was present.
At the end of the incubation, HL protein was immunoprecipitated from
the cell-free media and cell lysates, and then analyzed by SDS-PAGE and
PhosphorImaging. The radioactivity in the immunoreactive bands was
quantified. Panels A and B show part of the
PhosphorImage and the quantitative results for the cell-free media and
cell lysates, respectively. The positions of the 58- and 53-kDa bands
are indicated. In panel B, the quantitative data for the 58- and 53-kDa bands are given as upward and downward
bars, respectively. The results are representative for three
similar experiments.
|
|
Activation and Resistance to Endoglycosidase H--
The
electrophoretic mobility of [35S]HL secreted in the
absence or presence of CCCP, monensin, or colchicin was not affected by
overnight incubation with Endo-H (Fig.
7A). Hence, secreted HL was
completely Endo-H resistant. As a reference, we used
[35S]HL that was secreted by cells in the presence of
1-deoxymannojirimycin, which prevents the maturation of the
N-glycans from high-mannose to complex-type. This HL
migrated as a single 53-kDa band, the mobility of which was almost
completely shifted to 47 kDa corresponding to deglycosylated HL upon
digestion with Endo-H (Fig. 7A). Of the two HL bands
immunoprecipitated from control cell lysates, the 58-kDa band was
Endo-H resistant whereas the 53-kDa band was sensitive to Endo-H (Fig.
7B). Upon digestion, the 53-kDa band was completely shifted
to a higher mobility, partly to the position of 47 kDa, and partly to
the position of a 51-kDa band. The mobility of the latter band was not
altered upon prolonged incubation with additional Endo-H (not shown),
and may reflect HL with one Endo-H-resistant and one Endo-H-sensitive
oligosaccharide. Similar results were obtained with
[35S]HL in lysates from CCCP- and colchicin-treated
cells. With monensin-treated cells, however, part of the
[35S]HL migrating at the 53-kDa position was not shifted
to a higher mobility upon digestion with Endo-H and thus appeared
to be Endo-H resistant. These data suggest that the accumulation of
intracellular HL activity observed in monensin-treated cells coincides
with the production of a 53-kDa, mainly Endo-H resistant form of
HL.

View larger version (70K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of various inhibitors on the Endo-H
sensitivity of HL. Experiments were performed as described in the
legend to Fig. 6, except that prior to electrophoretic separation, the
immunoprecipitated proteins were incubated overnight at 37 °C
without ( ) or with (+) Endo-H. As a positive control for Endo-H
activity, a secretion medium from a 3-h incubation of rat hepatocytes
with 1 mM 1-deoxymannojirimycin (DMM) was
included. Panel A and B show the PhosphorImages
of the gels obtained with cell-free media and cell lysates,
respectively. The positions of the 58- and 53-kDa HL protein forms, as
well as the 47-kDa deglycosylated form are indicated. Data are
representative for two similar experiments.
|
|
Oligomeric Structure and Catalytic Activity of HL--
Since we
could not attribute the acquisition of catalytic activity to a
particular change in the glycosylation state of HL protein, we
attempted to correlate activation with possible noncovalent modifications of HL. Recent reports have indicated that catalytically active rat and human HL exist predominantly as noncovalent homodimers (37, 38). We therefore determined the oligomeric state of intracellular
and secreted HL by monitoring the sedimentation profile in sucrose
gradients. Aliquots of cell lysates and secretion media were loaded
onto linear sucrose gradients which were subjected to overnight
ultracentrifugation. Preliminary experiments showed that heparin had to
be present throughout the gradients to prevent formation of large HL
containing aggregates with the secretion media, whereas both heparin
and CHAPS (4 mM) were necessary to prevent aggregate
formation with the cell lysates. When secretion media were run under
these conditions, HL activity and HL protein sedimentated as a
homogeneous band (Fig. 8, lower
panel) at a position intermediate between the sedimentation
markers albumin (4.3 S) and IgG (7 S). Partly purified HL from rat
liver perfusates ran at the same position (data not shown). The
sedimentation coefficient of this band was rougly estimated at 5.8 S,
which is consistent with the dimeric structure of catalytically active
HL. No indications were found for the existence of a separate
population of HL protein in the 3 to 4 S region corresponding to
monomeric HL. The sedimentation profile of HL activity from cell
lysates was similar to that of secreted HL (Fig. 8, upper
panel), with a major band of about 5.8 S. In contrast, HL protein
sedimentated as a broad band that extended from the 5.8 S position to
more than 8 S. HL activity coincided with the slow-migrating part of HL
protein, whereas the fast-migrating part of HL protein was associated
with very low triglyceridase activity. The specific enzyme activity of
the 5.8 S protein form in the cell lysate was approximately 40 milliunits/µg, compared with 50 milliunits/µg for the 5.8 S form in
the secretion media. The specific enzyme activity of the
faster-migrating protein forms in the cell lysate (fractions 4 to 6)
ranged from 10 to 16 milliunits/µg. Also in the cell lysates, the
existence of a separate population of HL protein in the 3 to 4 S region
corresponding to monomeric HL was not evident.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 8.
Sucrose gradient sedimentation profiles of
intracellular and secreted HL. Hepatocytes were incubated for
3 h in the presence of 25 units/ml heparin and 20% serum, and
then cell-free media and cell lysates were prepared. Aliquots of the
cell-free media (lower panel) and cell lysates (upper
panel) were layered on top of a linear 5-20% (w/w) sucrose
gradient containing 25 units/ml heparin and 4 mM CHAPS.
After centrifugation, 13 fractions of the gradient were recovered by
aspiration from the bottom of the tube. HL activity (closed
symbols) and HL protein (open symbols) was measured for
each fraction. The position of bovine albumin (4.3 S) and rabbit IgG (7 S) in parallel gradients is indicated by the arrows. The
data are representative for three independent experiments.
|
|
 |
DISCUSSION |
The data presented here confirm our previous report that newly
synthesized HL protein is apparently activated during maturation and
secretion in rat hepatocytes (13). This was also observed for human HL
in HepG2 cells (14). This activation was prevented by treating the
cells with inhibitors of RER glucosidases, which interfere with proper
oligosaccharide processing of the newly synthesized HL (13). Upon
incubation with castanospermine the specific enzyme activity of
intracellular HL decreased, which may suggest that activation is
closely coupled to glucose trimming in the RER. However, we show here
that a fall in the specific activity of intracellular HL was also
induced with CCCP, which interferes with transport of glycoproteins out
of the RER to the Golgi, but leaves oligosaccharide processing in the
RER essentially unaffected. Hence, glucose trimming alone appears not
to be sufficient for activation of HL, but is necessary for transport
of HL out of the RER; HL then matures into a catalytically active
protein in a vesicular compartment distal from the RER. The RER
glucosidases have been recently proposed to assist in the folding of
newly synthesized glycoproteins thereby making them transport competent (21). In contrast to CCCP and castanospermine, a marked increase in the
specific enzyme activity of intracellular HL was induced by treating
the cells with monensin, which interferes with intra-Golgi vesicular
transport (25), as well as with colchicin, which interferes with
post-Golgi transport in rat hepatocytes (26, 27). This finding clearly
demonstrates that HL has acquired full catalytic activity when
accumulating in the Golgi compartment. Our data are best explained by
the model that newly synthesized HL acquires catalytic activity during
or after transport out of the RER.
Lipoprotein lipase, which is closely related to hepatic lipase, has
also been shown to acquire catalytic activity after the glucose
residues of the glycan side chains have been removed. Studies with
monensin in mouse brown fat adipocytes (39) and CCCP in 3T3-L1
adipocytes (40) led to the conclusion that LPL is activated after
transport of the protein from the RER into the Golgi. This was
supported by the observation that incubation of adipocytes with
brefeldin A, which induces the fusion of the RER with the Golgi
compartment, results in the intracellular accumulation of fully active
LPL (41). In our studies using freshly isolated rat hepatocytes,
maturation and secretion of HL was not affected by brefeldin A (data
not shown), possibly due to the rapid detoxification of the drug by
these cells (42). In HepG2 cells, brefeldin A induced the intracellular
accumulation of catalytically active HL (14); moreover, the inactive HL
that accumulated in castanospermine-treated HepG2 cells was converted
to fully active HL upon co-incubation with brefeldin A (14). These
combined data suggest that both HL and LPL require transport to the
Golgi compartment to become catalytically active. In contrast, Ben-Zeev
et al. (43) reported that LPL accumulated intracellularly as
a fully active enzyme when expressed as a hybrid with a C-terminal KDEL
sequence. As this sequence was thought to function as an RER retention
signal, the authors concluded that activation of LPL does occur before the protein reaches the Golgi compartment. Recent studies have demonstrated, however, that the KDEL sequence may function as a
retrieval signal; KDEL-bearing proteins are cycled back into the RER
from the Golgi or even beyond (44-46). Therefore, the catalytically active LPL-KDEL hybrid that accumulates in the RER may have been activated in the Golgi before being cycled back into the RER.
Our data indicate that catalytic activity co-varies with the presence
of the 58-kDa Endo-H resistant form of HL in CCCP and colchicin-treated
cells, and with the 53 kDa, mainly Endo-H resistant form in
monensin-treated cells. N-Glycoproteins are processed from
an Endo-H sensitive into an Endo-H-resistant form upon trimming of
mannose residues by Golgi mannosidases. These observations suggest
therefore, that the activation of HL is closely linked to, or occurs
only after, some of the mannoses on the glycan chains have been trimmed
off by the Golgi mannosidases. However, cells incubated with
1-deoxymannojirimycin secrete a 53 kDa, fully Endo-H sensitive form of
HL whose specific enzyme activity is virtually identical to that of
control HL (Fig. 7; Ref. 19). Therefore, trimming of the
oligosaccharides on HL by the Golgi mannosidases is not crucial for the
acquisition of triglyceridase activity. Taken together, these data
demonstrate that activation of HL cannot be attributed to a change in
its glycosylation state detectable by SDS-PAGE or Endo-H sensitivity.
Our observation that intracellular HL protein is present in complexes
with various sedimentation velocities, and that the catalytic activity
is associated with the slow-sedimenting protein forms suggests that
activation of HL coincides with changes in the oligomeric state of HL
protein. Catalytically active rat and human HL has recently been shown
to exist predominantly as noncovalent homodimers (37, 38). HL activity
in both secretion media and cell lysates was linked to protein forms
that sedimented as approximately 5.8 S particles, which is consistent
with the dimeric structure. We did not find evidence for the existence
of (inactive) HL in the 3-4 S range corresponding to the monomeric
protein. Instead, cell lysates but not secretion media contained HL
protein with low or no catalytic activity that predominantly
sedimentated as particles of 7 S and higher. This shows that (inactive)
HL is present in multimeric complexes, either as homo-oligomers or with other proteins. Together with our previous observations that inactive, intracellular HL protein can be secreted as active HL in the absence of
protein de novo synthesis (13, 14), these findings suggest that activation of HL involves release of the dimeric form from the
larger complexes. Although the intracellular localization of these
multimer complexes is unknown at present, it is tempting to speculate
that they are present in the RER. It is well established now that
virtually all newly synthesized N-glycoproteins temporarily associate with one or more chaperone proteins that are abundant in the
RER and assist in their proper folding (21, 22, 47). CCCP blocks
release of endoplasmic reticulum proteins from their chaperones
probably by depleting endoplasmic reticulum-ATP levels (48).
Castanospermine interferes with proper glycoprotein folding (21, 22),
thereby favoring formation of complexes with itself or with other
endoplasmic reticulum proteins. Transport of HL proteins out of the RER
will move them away from the numerous RER chaperones that may block
their full activation. Further studies are required to establish the
composition and intracellular localization of the multimer complexes,
and the precursor-product relationship with the active HL dimers.
In conclusion, we have shown here that activation of newly synthesized
HL protein is associated with a change in the oligomeric state of HL
that occurs during or after transport from the RER to the Golgi
compartment. The necessity to exit the RER in order to become activated
is not unique to lipases, but has recently also been reported for two
membrane-bound N-glycoproteins, the macrophage mannose
receptor (49) and the trans-Golgi network protease furin (50). The
modification that causes activation of these proteins has not been
identified, but was shown not to depend on oligosaccharide processing
per se. It may involve a rather subtle covalent modification
not detected by the rather course methods of SDS-PAGE and Endo-H
digestion. Alternatively, activation of these proteins may be due to
noncovalent changes in their structure, similar to HL. Hence, our
observations on the role of the oligomeric state in activation of newly
synthesized HL may bear relevance to other proteins as well.
 |
FOOTNOTES |
*
This work was supported by Dutch Heart Foundation Grant
91.075.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Biochemistry,
Erasmus University Rotterdam, P. O. Box 1738, 3000 DR Rotterdam, The
Netherlands. Tel.: 31-10-4087325; Fax: 31-10-4089472; E-mail: verhoeven@BC1.FGG.EUR.NL.
 |
ABBREVIATIONS |
The abbreviations used are:
HL, hepatic lipase;
CCCP, carbonyl cyanide m-chlorophenyl hydrazone;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate;
Endo-H, endo- -N-acetylglucosaminidase H;
JBAM, jack bean
-D-mannoside mannohydrolase;
PAGE, polyacrylamide gel
electrophoresis;
PBS, phosphate-buffered saline;
RER, rough endoplasmic
reticulum;
LPL, lipoprotein lipase;
MOPS, 4-morpholinepropanesulfonic
acid;
CSP, castanospermine.
 |
REFERENCES |
| 1.
|
Jackson, R. L.
(1983)
in
The Enzymes
(Boyer, P. D., ed), Vol. XVI
, pp. 141-180, Academic Press, Inc., New York
|
| 2.
|
Breedveld, B.,
Schoonderwoerd, K.,
Verhoeven, A. J. M.,
Willemsen, R.,
and Jansen, H.
(1997)
Biochem. J.
321,
425-430
|
| 3.
|
Sanan, D. A.,
Fan, J.,
Bensadoun, A.,
and Taylor, J. M.
(1997)
J. Lipid Res.
38,
1002-1013[Abstract]
|
| 4.
|
Sultan, F.,
Lagrange, D.,
Jansen, H.,
and Griglio, S.
(1990)
Biochim. Biophys. Acta
1042,
150-152[Medline]
[Order article via Infotrieve]
|
| 5.
|
Chang, S.,
and Borensztajn, J.
(1993)
Biochem. J.
293,
745-750
|
| 6.
|
Ji, Z. S.,
Lauer, S. J.,
Fazio, S.,
Bensadoun, A.,
Taylor, J. M.,
and Mahley, R. W.
(1994)
J. Biol. Chem.
269,
13429-13436[Abstract/Free Full Text]
|
| 7.
|
Bamberger, M.,
Glick, J. M.,
and Rothblat, G. H.
(1983)
J. Lipid Res.
24,
869-876[Abstract]
|
| 8.
|
Marquez-Vidal, P.,
Azéma, C.,
Collet, X.,
Vieu, C.,
Chap, H.,
and Perret, B.
(1994)
J. Lipid Res.
35,
373-384[Abstract]
|
| 9.
|
Krapp, A.,
Ahle, S.,
Kersting, S.,
Hua, Y.,
Kneser, K.,
Nielsen, M.,
Gliemann, J.,
and Beisiegel, U.
(1996)
J. Lipid Res.
37,
926-936[Abstract]
|
| 10.
|
Barth, J. D.,
Jansen, H.,
Kromhout, D.,
Reiber, J. H. C.,
Birkenhäger, J. C.,
and Arntzenius, A. C.
(1987)
Atherosclerosis
68,
51-58[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Groot, P. H. E.,
van Stiphout, W. A. H. J.,
Krauss, X. H.,
Jansen, H.,
van Tol, A.,
van Ramshorst, E.,
Chin-On, S.,
Hofman, A.,
Cresswell, S. R.,
and Havekes, L.
(1991)
Arterioscler. Thromb.
11,
653-662[Abstract/Free Full Text]
|
| 12.
|
Busch, S. J.,
Barnhart, R. L.,
Martin, G. A.,
Fitzgerald, M. C.,
Yates, M. T.,
Mao, S. J. T.,
Thomas, C. E.,
and Jackson, R. L.
(1994)
J. Biol. Chem.
269,
16376-16382[Abstract/Free Full Text]
|
| 13.
|
Verhoeven, A. J. M.,
and Jansen, H.
(1991)
Biochim. Biophys. Acta
1086,
49-56[Medline]
[Order article via Infotrieve]
|
| 14.
|
Verhoeven, A. J. M.,
Neve, B. P.,
and Jansen, H.
(1999)
Biochem. J.
337,
133-140
|
| 15.
|
Doolittle, M. H.,
Wong, H.,
Davis, R. C.,
and Schotz, M. C.
(1987)
J. Lipid Res.
28,
1326-1333[Abstract]
|
| 16.
|
Wölle, J.,
Jansen, H.,
Smith, L. C.,
and Chan, L.
(1993)
J. Lipid Res.
34,
2169-2176[Abstract]
|
| 17.
|
Ben-Zeev, O.,
Stahnke, G.,
Liu, G.,
Davis, R. C.,
and Doolittle, M. H.
(1994)
J. Lipid Res.
35,
1511-1523[Abstract]
|
| 18.
|
Leitersdorf, E.,
Stein, O.,
and Stein, Y.
(1984)
Biochim. Biophys. Acta
794,
261-268[Medline]
[Order article via Infotrieve]
|
| 19.
|
Verhoeven, A. J. M.,
and Jansen, H.
(1990)
J. Lipid Res.
31,
1883-1893[Abstract]
|
| 20.
|
Laposata, E. A.,
Laboda, H. M.,
Glick, J. M.,
and Strauss, J. F., III
(1987)
J. Biol. Chem.
262,
5333-5338[Abstract/Free Full Text]
|
| 21.
|
Hammond, C.,
Braakman, I.,
and Helenius, A.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
913-917[Abstract/Free Full Text]
|
| 22.
|
Helenius, A.
(1994)
Mol. Biol. Cell
5,
253-265[Medline]
[Order article via Infotrieve]
|
| 23.
|
Burkhardt, J. K.,
and Argon, Y.
(1989)
J. Cell Sci.
92,
633-642[Abstract/Free Full Text]
|
| 24.
|
Doms, R. W.
(1990)
Methods Enzymol.
191,
841-854[Medline]
[Order article via Infotrieve]
|
| 25.
|
Tartakoff, A.
(1983)
Cell
32,
1026-1028[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Redman, C. M.,
Banerjee, D.,
Howell, K.,
and Palade, G. E.
(1975)
J. Cell Biol.
66,
42-59[Abstract/Free Full Text]
|
| 27.
|
Patzelt, C.,
Brown, D.,
and Jeanrenaud, B.
(1977)
J. Cell Biol.
73,
578-593[Abstract/Free Full Text]
|
| 28.
|
Jensen, G. L.,
and Bensadoun, A.
(1981)
Anal. Biochem.
113,
246-252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Seglen, P. O.
(1976)
Methods Cell Biol.
13,
29-83[Medline]
[Order article via Infotrieve]
|
| 30.
|
Jansen, H.,
Kalkman, C.,
Zonneveld, A. J.,
and Hülsmann, W. C.
(1979)
FEBS Lett.
98,
299-302[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Kihara, S.,
Wölle, J.,
Ehnholm, C.,
Chan, L.,
and Oka, K.
(1993)
J. Lipid Res.
34,
961-970[Abstract]
|
| 32.
|
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Snedecor, G. W.,
and Cochran, W. G.
(1980)
Statistical Methods
, 7th Ed.
, Iowa State University Press, Ames, IA
|
| 34.
|
Hebert, D. N.,
Foellmer, B.,
and Helenius, A.
(1995)
Cell
81,
425-433[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Van Leeuwen, J. E. M.,
and Kearse, K. P.
(1996)
J. Biol. Chem.
271,
9660-9665[Abstract/Free Full Text]
|
| 36.
|
Nebbia, C.,
Ceppa, L.,
Dacasto, M.,
Carletti, M.,
and Nachtmann, C.
(1999)
Drug Metab. Dispos.
27,
1039-1044[Abstract/Free Full Text]
|
| 37.
|
Berryman, D. E.,
Mulero, J. J.,
Hughes, L. B.,
Brasaemle, D. L.,
and Bensadoun, A.
(1998)
Biochim. Biophys. Acta
1382,
217-229[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Hill, J. S.,
Davis, R. C.,
Yang, D,
Wen, J.,
Philo, J. S.,
Poon, P. H.,
Phillip, M. L.,
Kempner, E. S.,
and Wong, H.
(1996)
J. Biol. Chem.
271,
22931-22936[Abstract/Free Full Text]
|
| 39.
|
Masuno, H.,
Schultz, C. J.,
Park, J.-W.,
Blanchette-Mackie, E. J.,
Mateo, C.,
and Scow, R. O.
(1991)
Biochem. J.
277,
801-809
|
| 40.
|
Park, J.-W.,
Lee, S.-Y.,
Yang, J.-Y.,
Rho, H.-W.,
Park, B.-H.,
Lim, S.-M.,
Kim, J.-S.,
and Kim, H.-R.
(1997)
Biochim. Biophys. Acta
1344,
132-138[Medline]
[Order article via Infotrieve]
|
| 41.
|
Park, J.-W.,
Blanchette-Mackie, E. J.,
and Scow, R. O.
(1996)
Biochem. J.
317,
125-134
|
| 42.
|
Oda, K.,
Fujiwara, T.,
and Ikehara, Y.
(1990)
Biochem. J.
265,
161-167[Medline]
[Order article via Infotrieve]
|
| 43.
|
Ben-Zeev, O.,
Doolittle, M. H.,
Davis, R. C.,
Elovson, J.,
and Schotz, M. C.
(1992)
J. Biol. Chem.
267,
6219-6227[Abstract/Free Full Text]
|
| 44.
|
Pelham, H. R. B.
(1991)
Curr. Opin. Cell Biol.
3,
585-591[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Peter, F.,
Nguyen Van, P.,
and Soling, H.-D.
(1992)
J. Biol. Chem.
267,
10631-10637[Abstract/Free Full Text]
|
| 46.
|
Griffiths, G.,
Ericsson, M.,
Krijnse-Locker, J.,
Nilsson, T.,
Goud, B.,
Soling, H.-D.,
Tang, B. L.,
Wang, G. H.,
and Hong, W.
(1994)
J. Cell Biol.
127,
1557-1574[Abstract/Free Full Text]
|
| 47.
|
Ou, W.-J.,
Cameron, P. H.,
Thomas, D. Y.,
and Bergeron, J. J. M.
(1993)
Nature
364,
771-776[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Dorner, A. J.,
Wasley, L. C.,
and Kaufman, R. J.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
7429-7432[Abstract/Free Full Text]
|
| 49.
|
Pontow, S. E.,
Blum, J. S.,
and Stahl, P. D.
(1996)
J. Biol. Chem.
271,
30736-30740[Abstract/Free Full Text]
|
| 50.
|
Vey, M.,
Schafer, W.,
Berghofer, S.,
Klenk, H. D.,
and Garten, W.
(1994)
J. Cell Biol.
127,
1829-1842[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
O. Ben-Zeev and M. H. Doolittle
Maturation of Hepatic Lipase: FORMATION OF FUNCTIONAL ENZYME IN THE ENDOPLASMIC RETICULUM IS THE RATE-LIMITING STEP IN ITS SECRETION
J. Biol. Chem.,
February 13, 2004;
279(7):
6171 - 6181.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|